Latest in Cardiology from ACC.org

• CVD Risk Scores, CV Health Metrics Predict Greater Cancer Risk
  Worse cardiovascular disease risk scores or cardiovascular health metrics predict greater cancer risk, despite heterogeneity in cardiovascular disease risk metrics and cancer types, according to a study published July 15 in JACC: CardioOncology.
• SUMMIT Analysis: Does BMI and Central Adiposity Affect Tirzepatide Outcomes For HFpEF?
  Although tirzepatide showed no heterogeneity in primary cardiovascular outcomes for differing baseline BMI or central adiposity, individuals with heart failure (HF) with preserved ejection fraction (HFpEF) with higher BMI at baseline showed greater improvement in six-minute walking distance...
• ACCEL Lite: Hypertension Diagnosis and Management: Renal Denervation and Newer Agents on the Horizon
  In this interview, Dr. Alison L. Bailey and Dr. Keith C. Ferdinand explore the evolving landscape of hypertension management, highlighting new evidence supporting the benefits of tight blood pressure control across diverse populations.
• 18F Flurpiridaz PET MPI: New Horizons in Cardiac Imaging
  Fluorine-18 (18F) flurpiridaz is a radiotracer for positron emission tomography (PET) myocardial perfusion imaging (MPI) newly approved by the Food and Drug Administration (FDA), offering several advantages due to its favorable physical properties.
• Proposed 2026 Medicare Physician Fee Schedule: An ACC Advocacy Deep Dive
  The Centers for Medicare and Medicaid Services (CMS) has released the 2026 Medicare Physician Fee Schedule (PFS) proposed rule, updating the PFS conversion factor from $32.3465 to $33.5875 for qualifying alternative payment model (APM) participants and $33.4209 for non-qualifying APM participants...